Sign In
Buy VOR
$21.15
-0.650 (-2.98%)
At Close: Jul 31, 2026
Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference
08:00am, Monday, 03'rd Feb 2025
CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host vi
Vor Biopharma Inc. (VOR)'s Technical Outlook is Bright After Key Golden Cross
10:56am, Monday, 27'th Jan 2025
Vor Biopharma Inc. (VOR) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, VOR's 50-day simple moving average crossed above its
Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors
09:00am, Wednesday, 08'th Jan 2025
CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Mr. Erez Kalir to its Board of Direc
Vor Bio Announces $55.6 Million Private Placement
09:00am, Friday, 27'th Dec 2024
Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33 ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with Myl
CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced updated clinical data from its ongoing Phase 1/2 VBP101
Vor Bio price target lowered to $8 from $10 at Oppenheimer
02:27pm, Friday, 08'th Nov 2024
Oppenheimer analyst Matthew Biegler lowered the firm's price target on Vor Bio to $8 from $10 and keeps an Outperform rating on the shares following the Q3 report. The firm cites updated spending esti
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
07:00am, Monday, 30'th Sep 2024
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new C
What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?
09:35am, Friday, 06'th Sep 2024
Thursday, Vor Biopharma Inc. VOR announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory acute myeloid leukemia (AML) receiving trem-cel followed by My
New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies
04:01pm, Thursday, 05'th Sep 2024
CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced new clinical data from its ongoing Phase 1/2 VBP101 st
Vor Bio to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 28'th Aug 2024
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming inve
Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update
04:05pm, Thursday, 08'th Aug 2024
CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 02'nd Aug 2024
CAMBRIDGE, Mass., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of July 31, 2024, the Compensation C
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Tuesday, 09'th Jul 2024
CAMBRIDGE, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of July 1, 2024, the Compensation Co
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Tuesday, 04'th Jun 2024
CAMBRIDGE, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of June 1, 2024, the Compensation Co
Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
04:05pm, Thursday, 09'th May 2024
CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended March
